Alterity Therapeutics reported progress in its clinical development programs for Multiple System Atrophy (MSA) during fiscal year 2024. The company completed enrollment in its Phase 2 ATH434-201 trial with 77 early-stage MSA patients, with topline data expected in January 2025. An independent Data Monitoring Committee recommended the study continue without modification after its third safety review.Interim data from the ATH434-202 biomarker study showed encouraging results, with 43% of participants demonstrating improvement on the Unified MSA Rating Scale after 6 months of treatment. Clinical responders showed reduced iron accumulation on MRI in key brain regions and stable levels of neurofilament light chain, a marker of neuronal injury. The company's natural history study, bioMUSE, continued generating valuable data to optimize trial design.The company reported a net loss of A$19.1 million for FY2024 compared to A$13.8 million in FY2023, with research and development expenses increasing to A$18.6 million from A$13.2 million. Cash and cash equivalents were A$12.6 million as of June 30, 2024. The company completed several capital raises during the year totaling approximately A$10.1 million to advance its clinical programs.

Alterity Therapeutics reported progress in its clinical development programs for Multiple System Atrophy (MSA) during fiscal year 2024. The company completed enrollment in its Phase 2 ATH434-201 trial with 77 early-stage MSA patients, with topline data expected in January 2025. An independent Data Monitoring Committee recommended the study continue without modification after its third safety review.Interim data from the ATH434-202 biomarker study showed encouraging results, with 43% of participants demonstrating improvement on the Unified MSA Rating Scale after 6 months of treatment. Clinical responders showed reduced iron accumulation on MRI in key brain regions and stable levels of neurofilament light chain, a marker of neuronal injury. The company's natural history study, bioMUSE, continued generating valuable data to optimize trial design.The company reported a net loss of A$19.1 million for FY2024 compared to A$13.8 million in FY2023, with research and development expenses increasing to A$18.6 million from A$13.2 million. Cash and cash equivalents were A$12.6 million as of June 30, 2024. The company completed several capital raises during the year totaling approximately A$10.1 million to advance its clinical programs.